Select the drug indication to add to your list


Bleeding disorders
Only 4 drugs may be compared at once

Generic Name and Formulations:

Coagulation Factor XIII A-Subunit (recombinant) 2000–3125 IU; per vial; lyophilized pwd for IV inj after reconstitution; preservative-free.


Novo Nordisk

Select therapeutic use:

Indications for TRETTEN:

Routine prophylaxis of bleeding in patients with congenital factor XIII (FXIII) A-subunit deficiency. Limitations of use: not for use in patients with congenital factor XIII B-subunit deficiency.

Adults and Children:

Give by IV inj at a rate of max 1–2mL/min. Initially 35 IU/kg once monthly to achieve a target trough FXIII activity level ≥10% using a validated assay. Consider dose adjustment if adequate coverage not achieved. Do not administer with other infusion solutions.


Should be initiated under supervision of an experienced physician. Discontinue immediately and treat appropriately if anaphylaxis or hypersensitivity reactions occur. Conditions that predispose to thrombosis; monitor for signs/symptoms of thrombosis after administration. Measure FXIII inhibitory antibody concentrations if expected plasma FXIII activity levels not attained or if breakthrough bleeding occurs. Pregnancy (Cat. C). Nursing mothers.

Pharmacological Class:

Clotting factor.


Thrombosis risk with concomitant factor VIIa; avoid.

Adverse Reactions:

Headache, pain in the extremities, injection site pain, increase in fibrin D-dimer levels; hypersensitivity reactions.

How Supplied:

Single-use vials—1 (w. diluent, supplies)